RZLT241115C2500
- 2.90
- 0.000.00%
Rezolute Newsroom
Rezolute to Participate in Upcoming Investor Conferences
Rezolute Price Target Announced at $12.00/Share by Wedbush
Rezolute Initiated With an Outperform at Wedbush
AAO 2024: Rezolute's RZ-402 Shows Promising Phase IIa Results in DME Patients
With 62% Ownership, Rezolute, Inc. (NASDAQ:RZLT) Boasts of Strong Institutional Backing
CCORF Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $9
Edward Nash Recommends Buy on Rezolute, Sets $9 Target Amidst Product Progress and Regulatory Advancements
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $14
Rezolute Executive Wladimir Hogenhuis Buys $20,017 in Company Stock
BTIG Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $15
Analysts' Opinions Are Mixed on These Healthcare Stocks: Rezolute (RZLT) and Gryphon Digital Mining (GRYP)
Express News | Rezolute Inc : Jefferies Raises Target Price to $14 From $10
JMP Securities Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $7
Buy Rating Affirmed for Rezolute Amidst Progressive Clinical Trials and Strong Financial Position
Rezolute Fiscal Q4 Net Loss Widens; Shares Rise After-Hours
Rezolute | 10-K: FY2024 Annual Report
Earnings Flash (RZLT) REZOLUTE Posts Q4 Loss $-0.44
Press Release: Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Express News | Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
Express News | Rezolute Q4 Operating Expenses USD 23.102 Million